Martin Kiechle
Veselin Grozdanov
Karin M. Danzer- Department of Neurology, Ulm University, Ulm, Germany
The aggregation of α-synuclein (α-syn) is inseparably connected to Parkinson’s disease (PD). It is now well-established that certain forms of α-syn aggregates, oligomers and fibrils, can exert neurotoxicity in synucleinopathies. With the exception of rare familial forms, the vast majority of PD cases are idiopathic. Understanding the earliest molecular mechanisms that cause initial α-syn misfolding could help to explain why PD affects only some individuals and others not. Factors that chaperone the transition of α-syn’s physiological to pathological function are of particular interest, since they offer opportunities for intervention. The relationship between α-syn and lipids represents one of those factors. Membrane interaction is crucial for normal cellular function, but lipids also induce the aggregation of α-syn, causing cell toxicity. Also, disease-causing or risk-factor mutations in genes related to lipid metabolism like PLA2G6, SCARB2 or GBA1 highlight the close connection between PD and lipids. Despite the clear link, the ambivalent interaction has not been studied sufficiently so far. In this review, we address how α-syn interacts with lipids and how they can act as key factor for orchestrating toxic conversion of α-syn. Furthermore, we will discuss a scenario in which initial α-syn aggregation is determined by shifts in lipid/α-syn ratio as well as by dyshomeostasis of membrane bound/unbound state of α-syn.
Introduction
The abnormal aggregation of α-synuclein (α-syn) in the central nervous system defines neurodegenerative diseases such as Parkinson’s disease (PD), Dementia with Lewy bodies (DLB) and Multiple system atrophy (MSA) (Spillantini and Goedert, 2000). They all share common neuropathological hallmarks as a result of α-syn accumulation, known as Lewy bodies (LBs) and Lewy neurites (LNs). Although these age-related diseases are predominantly idiopathic, genetic studies demonstrate that the protein α-syn can directly contribute to pathologic events (Stefanis, 2012). However, initial mechanisms of α-syn misfolding that precede LB and LN formation remain elusive. This review summarizes recent advances in understanding the causes of α-syn aggregation.
α-Syn is an abundant protein in brain cells and is found alongside its nuclear localization mainly at the synapse of neurons (Iwai et al., 1995; Kahle et al., 2000; Pinho et al., 2018). About 3,000 α-syn molecules are present within a single synaptic bouton of a cortical rat neuron, highlighting its enormous concentration at synaptic terminals (Wilhelm et al., 2014). Since α-syn localizes to the synaptic compartment at a very late stage of synapse development, it was thought early on that it functions as a modulator of synaptic plasticity rather than taking part in synaptogenesis (Withers et al., 1997). Currently, we are in the process of deciphering the physiological functions of α-syn. Although there is no universal consensus, its function has increasingly been associated with regulating synaptic vesicle exo- and endocytosis (reviewed recently in Sulzer and Edwards, 2019). However, it was only in the last decade that we learned that α-syn can adopt a multimeric state at the presynapse, e.g., for promoting the SNARE complex formation or clustering synaptic vesicles and thereby attenuating neurotransmitter release (Burre et al., 2014; Wang et al., 2014). Studies showing that monomeric α-syn is the predominant species in the cytoplasm of cells were often carried out in (neuronal) cell lines that do not form a synaptic compartment (Theillet et al., 2016). However, (synaptic) membrane binding may be crucial for the temporal higher-order multimeric conformation and phospholipids seem to bear chaperone-like characteristics in this process. α-Syn is thereby in a dynamic conformational transition between α-helically structured in the membrane-bound situation – and monomeric, natively unfolded in the unbound state (Rovere et al., 2018). The classic paradigm, that α-syn is a natively unfolded protein has therefore been broadened by various findings in recent years (Cole et al., 2002; Bartels et al., 2011; Dettmer et al., 2013; Gould et al., 2014). The behavior of α-syn at the synapse is distinct from other proteins that also associate with the vesicle surface, such as synapsin I. In contrast to synapsin I, α-syn is highly mobile and binds synaptic vesicles only transiently as shown by fluorescence recovery after photobleaching (FRAP) experiments using GFP-tagged α-syn (Fortin et al., 2005). Remarkably, the localization of α-syn to the bouton was thereby dependent on neural activity, and α-syn quickly dispersed after strong stimulation.
The Structure of α-Synuclein Determines Its Lipid Binding Characteristics
The observation that α-syn is not tightly associated with synaptic vesicles might explain why it is usually purified as (monomeric) cytosolic protein from brain extracts, and not as constituent of the synaptic vesicle fraction (Takamori et al., 2006). However, isolation of synaptosomes under physiological salt conditions and immunoelectron microscopy verified the vesicle-binding properties of α-syn and showed that the majority (74.2%) of immunogold-labeled α-syn molecules were found on the surface of synaptic vesicles throughout the terminals (Vargas et al., 2017). But how is this transient affinity of α-syn to lipid membranes accomplished? The answer to this may lie in the structure of α-syn. Firstly, the primary structure of the 140 amino acids-long protein α-syn can be divided in three distinct regions. The N-terminal region (aa 1–60) contains imperfect repeats of 11 amino acids with a KTKEGV consensus sequence, predicted to form an amphipathic α-helix that resembles those found in apolipoproteins and known to bind and penetrate membranes (Clayton and George, 1998; Ahn et al., 2006). Secondly, the central domain (aa 61–95), also known as NAC domain (non-Aβ component of AD amyloid), is hydrophobic and prone to aggregation due to its propensity to form β-sheet-rich oligomeric conformations (Ueda et al., 1993; Giasson et al., 2001; Stefanis, 2012). This region further contains elements of the KTKEGV consensus sequence and together with the N-terminal domain, approximately two-thirds of the whole protein can form α-helices upon lipid binding. Thirdly, the negatively charged C-terminal domain (aa 96–140) is characterized by 33% acidic amino acids (Asp/Glu) and a proline-rich region that is responsible for the disordered C-terminal structure. However, not so long ago it was also suggested that the C-terminus associates with membranes in the presence of calcium (Lautenschlager et al., 2018). These intrinsic preconditions of the α-syn sequence as well as the lipid composition of the membrane to be bound including hydrophobicity, charge, or membrane curvature, most likely modulate membrane binding of α-syn. By mimicking synaptic-like lipid membranes in a solid-state and solution NMR spectroscopy approach, it was found that three different domains within the α-syn sequence interact differently with lipid membranes (Fusco et al., 2014). The most N-terminal α-helix (aa 6-25) anchored α-syn to the membrane surface with high affinity upon first contact, without being particular about lipid composition. In contrast, a central domain (aa 26-97) bound membranes with different intensities depending on lipid composition, suggesting a potential role as “modulating membrane sensor.” The C-terminal region (98-140) interacted only weakly with the membrane and behaved highly dynamic and independent from the other domains. It is therefore suggested that the central domain (aa 26-97) dictates whether to bind, or not to bind the lipid. Intriguingly, all familial mutations causing early- or late-onset PD (A30P, E46K, H50Q, G51D, A53T, A53E) are located within this crucial sequence, which could affect the specificity of membrane affinity or influence the N-terminal anchor. It was indeed found that some pathogenic α-syn mutants reduce lipid binding behavior, of which G51D and especially the helix-breaker mutation A30P had the strongest effect (Ruf et al., 2019). The A30P mutation was further found to negatively influence the N-terminal anchor, reasoning the substantial reduction in binding affinity of α-syn to small unilamellar vesicles (Fusco et al., 2016). However, for the early onset PD variant E46K, exactly the opposite was observed. The N-terminal anchor region (aa 6-25) was extended to aa 42, thereby increasing the membrane affinity.
Lipid Binding Modulates Initial α-Synuclein Aggregation
Does decreased or enhanced membrane affinity, based on amino acid exchange influence the propensity of α-syn to form abnormal aggregates? First of all, the aggregation kinetics of α-syn depend on a range of different solution conditions, of which the pH has the strongest impact (Buell et al., 2014). Aggregation kinetic experiments carried out at pH 6.5 in the presence of negatively charged lipid vesicles demonstrated that the rate of lipid-induced aggregation is indeed different for disease-associated α-syn mutations (Flagmeier et al., 2016). In this set of experiments, only the A53T mutation showed a clear enhancement for initial aggregate formation, whereas A30P was only slightly increased and E46K was much slower compared to wild type. In addition, the process of fibril elongation was only weakly affected by the mutants. Most importantly, Galvagnion et al. suggested that under quiescent conditions, the lipid-to-α-syn ratio is the most determinant factor for α-syn misfolding (Galvagnion et al., 2015). At high ratios of lipid/α-syn, only very little free, monomeric α-syn was present since the large excess of lipid resulted in all α-syn molecules being bound α-helically to the surface of membranes. In this experimental condition, α-syn aggregation was below the detection limit. A decrease in lipid concentration (low lipid/α-syn ratio), however, caused that α-syn was only partially bound to membranes and that a substantial proportion was freely available as a monomer in solution. This condition greatly favored the essential primary nucleation step on the lipid surface that gives rise to fibril formation. By using atomic force microscopy, Galvagnion et al. further found that only a fraction of vesicle-bound α-syn was able to serve as active nucleation seed, from which fibrils could sprout. Through these experiments, one could set up a hypothesis that in the situation where α-syn is bound to the membrane or is in the process of forming the α-helical structure, an aggregation-susceptible intermediate conformation could occur, which freely, unfolded monomeric α-syn could bind if available, resulting in abnormal aggregation (Figure 1). Since natively unfolded proteins hold heterogeneous conformational states per se and the free energy landscape of α-syn is highly dynamic, the existence of such an intermediate conformation is likely (Allison et al., 2009). Indeed, the presence of a partially folded intermediate conformation of α-syn has been suggested many years back (Uversky et al., 2001). A decrease in pH or increase in temperature resulted in a partially folded intermediate conformation of α-syn. The concentration of lipids could therefore represent an additional intracellular factor that shifts the equilibrium of α-syn between an aggregation-prone intermediate conformation and its natively folded/unfolded state. Future cryo-electron microscopy experiments could provide insights into such a state and deliver a complete view of membrane-induced α-syn folding. The lipid-water interface would be vital for primary nucleation, since it is known that interfaces play important roles in the aggregation of α-syn (Campioni et al., 2014). This simplified scenario for initial aggregate formation determined by a low lipid/α-syn ratio as well as altered concentrations of α-synlipid–bound and α-synfree could explain several PD-associated findings, like the α-syn-dosage effect for the development of PD. Increased α-syn expression levels by genetic locus duplication/triplication, variabilities in SNCA-promoter region REP1 or somatic copy number gains of α-syn all demonstrate the close relation of α-syn concentration and PD age of onset (Singleton et al., 2003; Chartier-Harlin et al., 2004; Maraganore et al., 2006; Fuchs et al., 2008; Mokretar et al., 2018). The lipid/α-syn ratio is likely to be lowered by elevated levels of α-syn at the synapse, thereby increasing the chance for lipid-induced spontaneous aggregation events. Another factor responsible for a shift in the lipid/α-syn ratio could be aging, which remains the highest risk factor for the development and progression of PD (de Lau and Breteler, 2006; Collier et al., 2011). More than half of the human brain’s dry weight is made up of lipids, and the incredible heterogeneous lipid composition of the brain changes significantly with age (Naudi et al., 2015). Depending on the class of lipids and the area of the brain, the concentration of some lipids increases with age, but the majority is substantially decreased. In particular, levels of cholesterol, gangliosides or glycerophospholipids, all enriched at synapses, are reduced with age (Rappley et al., 2009; Ledesma et al., 2012). Age-related lipid alterations in the brain could therefore lower the local lipid/α-syn ratio and increase the primary nucleation rate. It is worth mentioning that α-syn aggregation is not only triggered by phospholipids with small acidic headgroups, but also by anionic lipids that contain larger oligosaccharide headgroups like gangliosides (Gaspar et al., 2018). It was found that all major brain gangliosides were significantly decreased in male PD patients compared to healthy controls (Seyfried et al., 2018). Pilot studies further showed that treating PD Patients with GM1 ganglioside could provide a disease modifying therapy and that GM1 administration reduced the size of α-syn aggregates in a rodent AAV-α-syn overexpression model (Schneider et al., 2013, 2015, 2019). However, research of human brain lipidomics of different brain areas or cell types during aging in health and disease is limited. Prospective studies could provide exciting insights into whether lipid alterations (at the synapse) in the aged-brain modify the behavior of α-syn.
Figure 1. Schematic illustration of the discussed conformational states of α-syn. The unfolded, unbound and monomeric α-syn adopts a partially folded intermediate conformation at its very N-terminus upon membrane binding, leaving the NAC domain exposed for potential primary nucleation. Freely available monomeric α-syn could bind to the hypothesized intermediate conformation, facilitating initial lipid-induced amyloid oligomer and fibril formation. Under physiological conditions, α-syn quickly adopts an extended α-helical or a broken-helix conformation, which can also form physiological multimers that cluster synaptic vesicles. A change in the lipid/α-syn ratio, the lipid composition or the fraction of membrane bound vs. unbound α-syn could shift the balance between physiological and pathological paths.
Aberrant interaction of α-syn with biological membranes like enhanced membrane-binding also fits in the concept of lipid/α-syn ratio induced aggregation. As previously mentioned, the E46K mutation has a greatly increased membrane affinity. This mutation disrupts an N-terminal KTKEGV motif to KTKKGV and drastically destabilizes physiological aggregation-resistant multimers of α-syn, leading to enhanced levels of aggregation-prone monomeric α-syn (Dettmer et al., 2015). In addition, a recent report argues for a loss of α-syn’s membrane curvature-sensing ability due to E46K mutation, thereby misdirecting α-syn to non-physiological lipid interactants (Rovere et al., 2019). By introducing two additional E > K mutations in other KTKEGV motifs (E35K and E61K, termed “3K” with the E46K mutation), this effect was dose-dependently amplified, resulting in increased monomeric conformations of α-syn and induction of neurotoxic inclusions. By increasing monomeric α-syn, which additionally shows an increased spatio-temporal membrane binding behavior, the probability of primary nucleation on the surface of lipids would be greatly increased. Generation of a 3K α-syn mouse model strengthened the in vitro findings and impressively mirrored key characteristics of PD (Nuber et al., 2018). Due to increased membrane affinity and potentially an increase in the partially folded intermediate state, 3K α-syn accumulated extensively at presynaptic vesicles and formed Proteinase-K resistant, phosphorylated, and truncated α-syn deposits. Even young 3K mice showed large neuronal lipofuscin-like autofluorescent, but α-syn-positive deposits that increased with age and evolved into huge spherical aggregates with filamentous structures and a lipofuscin-rich center. This finding in particular is interesting in the light of the recent report, that LBs in the brain of PD patients consisted largely of fragmented lipids, vesicles and organelles (Shahmoradian et al., 2019). The combination of enhanced membrane association, the inability to form physiological multimers, and the low lipid/α-syn ratio by α-syn overexpression could reason the striking phenotype of the 3K model. But how do the familial α-syn mutations A30P and G51D fit into the picture? To start with, the reduced lipid binding properties of A30P and G51D do not mean that lipid binding is completely abolished, but rather that the affinity is reduced compared to wildtype α-syn. Since they also destabilize physiological multimers and thereby increase the moiety of aggregation-prone monomeric α-syn, in theory only the rate of primary nucleation would be slower. Indeed, A30P as well as G51D were found to attenuate aggregation, although inconsistent reports for A30P exist (Lemkau et al., 2012; Fares et al., 2014). In addition, elevated levels of a specific conformation of the N-terminal amphipathic α-helix termed SL1 has been observed for A30P, E46K and A53T compared to wildtype (Bodner et al., 2010). Here, only a short α-helix comprising residues 3–25 was membrane-bound, leaving the hydrophobic NAC region dynamically disordered and prone for disease-associated aggregate formation. However, an alternative pathologic loss of function mechanism for A30P and G51D, independent of lipid-induced aggregation, cannot be excluded.
The Lipid Composition Alters α-Synuclein Aggregation
Membrane-interaction is part of the physiological function of α-syn. The lipid-binding properties are predefined by the first 60 amino acids of the N-terminal sequence with its 18% positively charged lysine residues, directing the affinity for anionic lipids. Upon membrane binding, α-syn forms amphipathic α-helices. Several conformations have been observed, like a single extended α-helix that is over 90 aa long, the previously mentioned short α-helix comprising residues 3–25 or two α-helices interrupted by a short break (Chandra et al., 2003; Jao et al., 2004, 2008; Bodner et al., 2010). Moreover, α-syn was found to be a membrane curvature-sensing protein, preferentially binding to small unilamellar vesicles with diameters similar to those of synaptic vesicles (Middleton and Rhoades, 2010). The mechanisms by which lipids orchestrate the physiological multimerization or induce pathological aggregation of α-syn, however, have yet to be clarified. Several studies analyzed physical and chemical properties of biological membranes or lipids and how they influence the aggregation propensity of α-syn. Amyloid fibril formation of α-syn has been observed for lipids with high solubility in aqueous solution and short hydrocarbon chains (Galvagnion et al., 2016). It was further discovered that exosomes with their high GM1 and GM3 ganglioside concentration provide an environment for accelerated α-syn aggregation, an interesting finding considering exosomal cell-to-cell transmission of α-syn oligomers (Danzer et al., 2012; Grey et al., 2015). Likewise, oxidized cholesterol metabolites, that were found to be increased in brains of patients with LBD, induced fibrillation of α-syn (Bosco et al., 2006). In vitro experiments also showed that polyunsaturated fatty acids (like α-linolenic acid or eicosapentaenoic acid) alone or esterified with phospholipids promote the formation of α-syn oligomers along with cytotoxicity, whereas saturated fatty acids (like stearic acid or arachidic acid) decreased levels of α-syn oligomers (Perrin et al., 2001; Sharon et al., 2003; Snead and Eliezer, 2014). These data, showing that lipids of different classes are able to induce disease-associated misfolding of α-syn, favor a model in which lipids play a significant role for the development of synucleinopathies, although the context of a relevant biological setting was mostly missing. Overexpression of α-syn in several PD-related cell culture systems and in vivo led to higher levels of di-/triglycerides with increased concentrations of unsaturated fatty acids, especially oleic acid (Fanning et al., 2019). This change in lipid class composition was accompanied by buildup of aggregated and phosphorylated α-syn species along increased cytotoxicity. The enrichment of oleic acid-containing lipids in membranes most likely enhances membrane fluidity and affects its curvature. The authors suggested that the rate of membrane-associated α-syn is enhanced by increased oleic acid levels, which mediated α-syn toxicity. Although the origin of higher amounts of oleic acid is unknown, decreasing the levels by inhibiting its rate-limiting enzyme stearoyl-CoA desaturase (SCD) proved to be protective and broke the vicious pathological circle (Fanning et al., 2019). Targeting SCD is a promising therapeutic strategy, which was also found independently by Vincent et al. Here, inhibiting SCD reduced α-syn toxicity in human induced pluripotent stem cell neuronal models (Vincent et al., 2018). These studies were the first to target α-syn oligomerization by exploiting its membrane-binding nature.
Relation Between Lipids, Different Oligomeric α-Synuclein Species and Toxicity
From what it described above, it is clear that lipids can act as trans-factors and modulate α-syn aggregation. However, different trans-factors favor the formation of different oligomeric species with distinct physico-chemical and toxic characteristics (Bousset et al., 2013). It is therefore only logical to ask if lipid binding favors the formation of specific oligomeric species with distinct toxicity. To date, this question remains to be answered. Suzuki et al. employed a GBA1 knockout model to demonstrate that disbalance of glycosylceramide results in the accumulation of PKA-resistant α-syn (Suzuki et al., 2015). However, the exact species of α-syn remained unspecified. The spectrum of different oligomeric α-syn species is rapidly growing and populated by a very high number of small to intermediate molecular-weight α-syn oligomers and different strains of high molecular-weight fibrils. Virtually all of the characterized species have been ascribed some toxic function (for an exhaustive review, see Ingelsson, 2016; Alam et al., 2019). Oligomers can induce cytoskeletal perturbances, ER stress, mitochondrial dysfunction, increased ROS production, ion flux dysbalance, synaptotoxicity and inhibition of the cellular protein synthesis and degradation (Lindersson et al., 2004; Danzer et al., 2007, 2009; Vekrellis et al., 2011; Colla et al., 2012; Choi et al., 2013; Deas et al., 2016). Lipid binding itself is required for some of these observed toxic effects: small, β-sheet-rich oligomers form pores in lipid bilayer membranes and result in detrimental ion flux and vesicle rupture (Danzer et al., 2007; Flavin et al., 2017). Furthermore, α-syn oligomers and fibrils have differential, detrimental effects on anterograde axonal transport (Prots et al., 2013). Large, fibrillar aggregates of α-syn show less direct toxicity to cells; however, they are unique in their capability to propagate α-syn aggregation by recruiting endogenous α-syn and result in complex synucleinopathies in animal models (Alam et al., 2019). Importantly, the toxic effects of oligomeric α-syn species are observed not only in vitro, but also in vivo (Winner et al., 2011). The traditional view on α-syn oligomers suggests the physiological existence of soluble, endogenous non-toxic α-syn oligomers that are converted to toxic species by pathologic mechanisms. These “physiological” oligomers were recently joined by the stable, membrane-bound tetramers described above. In this view, the (pathologic) binding of α-syn to lipids may stabilize aggregation-prone conformations and thus favor or inhibit the formation of toxic soluble oligomers. However, Killinger and colleagues recently challenged this traditional view by suggesting an alternative, monomer-only and lipid-centric hypothesis postulating that the apparent, soluble α-syn oligomers are in fact conformations of membrane-bound α-syn (Killinger et al., 2019). In this model, the formation of any α-syn oligomers is detrimental and the critical pathological step is the conversion of monomers into oligomers. The distinction between these two models remains technically challenging, but it will have tremendous impact on the choice of appropriate therapeutic strategy.
The Synapse as Early Point of Departure From Physiological to Pathological
Different anatomical sites and cell types have been proposed to be the site of initial α-syn aggregation. Indeed, α-syn is expressed at relatively high levels even in peripheral tissues. Erythrocytes, immune cells and fibroblasts are several cell types that can contain high levels of endogenous (and probably oligomeric) α-syn (Nakai et al., 2007; Hoepken et al., 2008). Interestingly, most of the observations of α-syn in peripheral cell types include processes with increased membrane dynamics. For example, α-syn expression and localization at cellular membranes is increased during the enucleation of erythrocyte precursors and during the phagocytosis of extracellular material (Nakai et al., 2007; Gardai et al., 2013; Abd-Elhadi et al., 2015). However, several factors may render CNS neurons specifically vulnerable to initial α-syn aggregation: different abundance of β-synuclein and molecular chaperones, increased metabolic rate, increased melanin and ROS, high turnover of membranes. Since α-syn localizes largely to the synapse of neurons, it is worth thinking about which synaptic membranes contain large amounts of di- or triglycerides. Lipidome analysis found porosomes, a domain of the presynaptic synaptosome, to be enriched in diglycerides, and that synaptic vesicles have high concentrations of triglycerides and sphingomyelins compared to the surrounding synaptosomal membrane (Lewis et al., 2014, 2017). Moreover, it is known for a long time that sphingomyelins are enriched in Lewy bodies, and that the activity of enzymes related to sphingolipid metabolism in the brain changes with age (den Jager, 1969; Sacket et al., 2009). An emerging consensus from various laboratories suggest the synapse as starting point for pathologic events in PD with axon terminals representing the initial site for α-syn aggregate formation. From a genetic perspective, several genes implicated in PD pathogenesis code for proteins related to synapse function (Soukup et al., 2018). First α-syn-related dysfunctions in rodent models were detected at the synapse, such as altered synaptic vesicle pool, deficits in neurotransmitter release or even redistribution of SNARE proteins (Garcia-Reitbock et al., 2010; Nemani et al., 2010; Scott et al., 2010; Phan et al., 2017). A substantial loss of synaptic terminals that preceded the death of dopaminergic neurons was observed in a mouse model with overexpression of mutant α-syn in the background of elevated dopamine (Mor et al., 2017). This state is reminiscent of human post-mortem brain studies that suggested synaptic decay as earliest pathology in PD (Beach et al., 2008; Cheng et al., 2010). In DLB patients, synaptic terminals were suggested to be the loci for α-syn aggregation and axonal retrograde transport with LB formation is the cellular counteracting strategy (Kramer and Schulz-Schaeffer, 2007). Using protein-fragment complementation assays in vivo, we have recently provided additional evidence that α-syn oligomerizes at the presynapse, giving rise to pathologically relevant α-syn species (Kiechle et al., 2019). Understanding how lipids are involved in synaptic α-syn aggregation during the aging process could hold promising treatment opportunities. The possibility that lipids act as effectors causing distinct α-syn strain variants is also currently being contemplated in the field of synucleinopathies (Ikenaka et al., 2019). Hence, modulating neuronal lipid synthesis in the brain could protect the synapse as most vulnerable compartment of neurons and allows to explore new therapeutic avenues for PD, DLB and MSA.
Author Contributions
MK designed and wrote the manuscript. VG and KD wrote and edited the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This work was funded by the Emmy Noether Program DA 1657/2-1 of the Deutsche Forschungsgemeinschaft (MK, VG, and KD).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Abd-Elhadi, S., Honig, A., Simhi-Haham, D., Schechter, M., Linetsky, E., Ben-Hur, T., et al. (2015). Total and proteinase K-resistant alpha-synuclein levels in erythrocytes, determined by their ability to bind phospholipids, associate with Parkinson’s disease. Sci. Rep. 5:11120. doi: 10.1038/srep11120
Ahn, K. J., Paik, S. R., Chung, K. C., and Kim, J. (2006). Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. J. Neurochem. 97, 265–279. doi: 10.1111/j.1471-4159.2006.03731.x
Alam, P., Bousset, L., Melki, R., and Otzen, D. E. (2019). alpha-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J. Neurochem. 150, 522–534. doi: 10.1111/jnc.14808
Allison, J. R., Varnai, P., Dobson, C. M., and Vendruscolo, M. (2009). Determination of the free energy landscape of alpha-synuclein using spin label nuclear magnetic resonance measurements. J. Am. Chem. Soc. 131, 18314–18326. doi: 10.1021/ja904716h
Bartels, T., Choi, J. G., and Selkoe, D. J. (2011). alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107–110. doi: 10.1038/nature10324
Beach, T. G., Adler, C. H., Sue, L. I., Peirce, J. B., Bachalakuri, J., Dalsing-Hernandez, J. E., et al. (2008). Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 115, 445–451. doi: 10.1007/s00401-007-0313-7
Bodner, C. R., Maltsev, A. S., Dobson, C. M., and Bax, A. (2010). Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson’s disease revealed by solution NMR spectroscopy. Biochemistry 49, 862–871. doi: 10.1021/bi901723p
Bosco, D. A., Fowler, D. M., Zhang, Q., Nieva, J., Powers, E. T., Wentworth, P., et al. (2006). Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat. Chem. Biol. 2, 249–253. doi: 10.1038/nchembio782
Bousset, L., Pieri, L., Ruiz-Arlandis, G., Gath, J., Jensen, P. H., Habenstein, B., et al. (2013). Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 4:2575. doi: 10.1038/ncomms3575
Buell, A. K., Galvagnion, C., Gaspar, R., Sparr, E., Vendruscolo, M., Knowles, T. P., et al. (2014). Solution conditions determine the relative importance of nucleation and growth processes in alpha-synuclein aggregation. Proc. Natl. Acad. Sci. U.S.A. 111, 7671–7676. doi: 10.1073/pnas.1315346111
Burre, J., Sharma, M., and Sudhof, T. C. (2014). alpha-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl. Acad. Sci. U.S.A. 111, E4274–E4283. doi: 10.1073/pnas.1416598111
Campioni, S., Carret, G., Jordens, S., Nicoud, L., Mezzenga, R., and Riek, R. (2014). The presence of an air-water interface affects formation and elongation of alpha-Synuclein fibrils. J. Am. Chem. Soc. 136, 2866–2875. doi: 10.1021/ja412105t
Chandra, S., Chen, X., Rizo, J., Jahn, R., and Sudhof, T. C. (2003). A broken alpha -helix in folded alpha -Synuclein. J. Biol. Chem. 278, 15313–15318. doi: 10.1074/jbc.M213128200
Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., et al. (2004). Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364, 1167–1169. doi: 10.1016/S0140-6736(04)17103-1
Cheng, H. C., Ulane, C. M., and Burke, R. E. (2010). Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67, 715–725. doi: 10.1002/ana.21995
Choi, B. K., Choi, M. G., Kim, J. Y., Yang, Y., Lai, Y., Kweon, D. H., et al. (2013). Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl. Acad. Sci. U.S.A. 110, 4087–4092. doi: 10.1073/pnas.1218424110
Clayton, D. F., and George, J. M. (1998). The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21, 249–254. doi: 10.1016/s0166-2236(97)01213-7
Cole, N. B., Murphy, D. D., Grider, T., Rueter, S., Brasaemle, D., and Nussbaum, R. L. (2002). Lipid droplet binding and oligomerization properties of the Parkinson’s disease protein alpha-synuclein. J. Biol. Chem. 277, 6344–6352. doi: 10.1074/jbc.M108414200
Colla, E., Jensen, P. H., Pletnikova, O., Troncoso, J. C., Glabe, C., and Lee, M. K. (2012). Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J. Neurosci. 32, 3301–3305. doi: 10.1523/JNEUROSCI.5368-11.2012
Collier, T. J., Kanaan, N. M., and Kordower, J. H. (2011). Ageing as a primary risk factor for Parkinson’s disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 12, 359–366. doi: 10.1038/nrn3039
Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., et al. (2007). Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27, 9220–9232. doi: 10.1523/JNEUROSCI.2617-07.2007
Danzer, K. M., Kranich, L. R., Ruf, W. P., Cagsal-Getkin, O., Winslow, A. R., Zhu, L., et al. (2012). Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7:42. doi: 10.1186/1750-1326-7-42
Danzer, K. M., Krebs, S. K., Wolff, M., Birk, G., and Hengerer, B. (2009). Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J. Neurochem. 111, 192–203. doi: 10.1111/j.1471-4159.2009.06324.x
de Lau, L. M., and Breteler, M. M. (2006). Epidemiology of Parkinson’s disease. Lancet Neurol. 5, 525–535. doi: 10.1016/S1474-4422(06)70471-9
Deas, E., Cremades, N., Angelova, P. R., Ludtmann, M. H., Yao, Z., Chen, S., et al. (2016). Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson’s disease. Antioxid. Redox Signal. 24, 376–391. doi: 10.1089/ars.2015.6343
den Jager, W. A. (1969). Sphingomyelin in Lewy inclusion bodies in Parkinson’s disease. Arch. Neurol. 21, 615–619. doi: 10.1001/archneur.1969.00480180071006
Dettmer, U., Newman, A. J., Luth, E. S., Bartels, T., and Selkoe, D. (2013). In vivo cross-linking reveals principally oligomeric forms of alpha-synuclein and beta-synuclein in neurons and non-neural cells. J. Biol. Chem. 288, 6371–6385. doi: 10.1074/jbc.M112.403311
Dettmer, U., Newman, A. J., Soldner, F., Luth, E. S., Kim, N. C., von Saucken, V. E., et al. (2015). Parkinson-causing alpha-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat. Commun. 6:8314. doi: 10.1038/ncomms8314
Fanning, S., Haque, A., Imberdis, T., Baru, V., Barrasa, M. I., Nuber, S., et al. (2019). Lipidomic Analysis of alpha-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment. Mol. Cell. 73:e1008. doi: 10.1016/j.molcel.2018.11.028
Fares, M. B., Ait-Bouziad, N., Dikiy, I., Mbefo, M. K., Jovicic, A., Kiely, A., et al. (2014). The novel Parkinson’s disease linked mutation G51D attenuates in vitro aggregation and membrane binding of alpha-synuclein, and enhances its secretion and nuclear localization in cells. Hum. Mol. Genet. 23, 4491–4509. doi: 10.1093/hmg/ddu165
Flagmeier, P., Meisl, G., Vendruscolo, M., Knowles, T. P., Dobson, C. M., Buell, A. K., et al. (2016). Mutations associated with familial Parkinson’s disease alter the initiation and amplification steps of alpha-synuclein aggregation. Proc. Natl. Acad. Sci. U.S.A. 113, 10328–10333. doi: 10.1073/pnas.1604645113
Flavin, W. P., Bousset, L., Green, Z. C., Chu, Y., Skarpathiotis, S., Chaney, M. J., et al. (2017). Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathol. 134, 629–653. doi: 10.1007/s00401-017-1722-x
Fortin, D. L., Nemani, V. M., Voglmaier, S. M., Anthony, M. D., Ryan, T. A., and Edwards, R. H. (2005). Neural activity controls the synaptic accumulation of alpha-synuclein. J. Neurosci. 25, 10913–10921. doi: 10.1523/JNEUROSCI.2922-05.2005
Fuchs, J., Tichopad, A., Golub, Y., Munz, M., Schweitzer, K. J., Wolf, B., et al. (2008). Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 22, 1327–1334. doi: 10.1096/fj.07-9348com
Fusco, G., De Simone, A., Gopinath, T., Vostrikov, V., Vendruscolo, M., Dobson, C. M., et al. (2014). Direct observation of the three regions in alpha-synuclein that determine its membrane-bound behaviour. Nat. Commun. 5:3827. doi: 10.1038/ncomms4827
Fusco, G., Pape, T., Stephens, A. D., Mahou, P., Costa, A. R., Kaminski, C. F., et al. (2016). Structural basis of synaptic vesicle assembly promoted by alpha-synuclein. Nat. Commun. 7:12563. doi: 10.1038/ncomms12563
Galvagnion, C., Brown, J. W., Ouberai, M. M., Flagmeier, P., Vendruscolo, M., Buell, A. K., et al. (2016). Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of alpha-synuclein. Proc. Natl. Acad. Sci. U.S.A. 113, 7065–7070. doi: 10.1073/pnas.1601899113
Galvagnion, C., Buell, A. K., Meisl, G., Michaels, T. C., Vendruscolo, M., Knowles, T. P., et al. (2015). Lipid vesicles trigger alpha-synuclein aggregation by stimulating primary nucleation. Nat. Chem. Biol. 11, 229–234. doi: 10.1038/nchembio.1750
Garcia-Reitbock, P., Anichtchik, O., Bellucci, A., Iovino, M., Ballini, C., Fineberg, E., et al. (2010). SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson’s disease. Brain 133(Pt 7), 2032–2044. doi: 10.1093/brain/awq132
Gardai, S. J., Mao, W., Schule, B., Babcock, M., Schoebel, S., Lorenzana, C., et al. (2013). Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson’s disease. PLoS One 8:e71634. doi: 10.1371/journal.pone.0071634
Gaspar, R., Pallbo, J., Weininger, U., Linse, S., and Sparr, E. (2018). Ganglioside lipids accelerate alpha-synuclein amyloid formation. Biochim. Biophys. Acta Proteins Proteom. 1866, 1062–1072. doi: 10.1016/j.bbapap.2018.07.004
Giasson, B. I., Murray, I. V., Trojanowski, J. Q., and Lee, V. M. (2001). A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380–2386. doi: 10.1074/jbc.M008919200
Gould, N., Mor, D. E., Lightfoot, R., Malkus, K., Giasson, B., and Ischiropoulos, H. (2014). Evidence of native alpha-synuclein conformers in the human brain. J. Biol. Chem. 289, 7929–7934. doi: 10.1074/jbc.C113.538249
Grey, M., Dunning, C. J., Gaspar, R., Grey, C., Brundin, P., Sparr, E., et al. (2015). Acceleration of alpha-synuclein aggregation by exosomes. J. Biol. Chem. 290, 2969–2982. doi: 10.1074/jbc.M114.585703
Hoepken, H. H., Gispert, S., Azizov, M., Klinkenberg, M., Ricciardi, F., Kurz, A., et al. (2008). Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp. Neurol. 212, 307–313. doi: 10.1016/j.expneurol.2008.04.004
Ikenaka, K., Suzuki, M., Mochizuki, H., and Nagai, Y. (2019). Lipids as trans-acting effectors for alpha-synuclein in the pathogenesis of Parkinson’s disease. Front. Neurosci. 13:693. doi: 10.3389/fnins.2019.00693
Ingelsson, M. (2016). Alpha-synuclein oligomers-neurotoxic molecules in Parkinson’s disease and other lewy body disorders. Front. Neurosci. 10:408. doi: 10.3389/fnins.2016.00408
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H. A., et al. (1995). The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467–475. doi: 10.1016/0896-6273(95)90302-x
Jao, C. C., Der-Sarkissian, A., Chen, J., and Langen, R. (2004). Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc. Natl. Acad. Sci. U.S.A. 101, 8331–8336. doi: 10.1073/pnas.0400553101
Jao, C. C., Hegde, B. G., Chen, J., Haworth, I. S., and Langen, R. (2008). Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. Proc. Natl. Acad. Sci. U.S.A. 105, 19666–19671. doi: 10.1073/pnas.0807826105
Kahle, P. J., Neumann, M., Ozmen, L., Muller, V., Jacobsen, H., Schindzielorz, A., et al. (2000). Subcellular localization of wild-type and Parkinson’s disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365–6373. doi: 10.1523/jneurosci.20-17-06365.2000
Kiechle, M., von Einem, B., Hofs, L., Voehringer, P., Grozdanov, V., Markx, D., et al. (2019). In vivo protein complementation demonstrates presynaptic alpha-synuclein oligomerization and age-dependent accumulation of 8-16-mer oligomer species. Cell Rep. 29, 2862–2874.e2869. doi: 10.1016/j.celrep.2019.10.089
Killinger, B. A., Melki, R., Brundin, P., and Kordower, J. H. (2019). Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let’s talk about the lipids in the room. NPJ Parkinsons Dis. 5:23. doi: 10.1038/s41531-019-0095-3
Kramer, M. L., and Schulz-Schaeffer, W. J. (2007). Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 27, 1405–1410. doi: 10.1523/Jneurosci.4564-06.2007
Lautenschlager, J., Stephens, A. D., Fusco, G., Strohl, F., Curry, N., Zacharopoulou, M., et al. (2018). C-terminal calcium binding of alpha-synuclein modulates synaptic vesicle interaction. Nat. Commun. 9:712. doi: 10.1038/s41467-018-03111-4
Ledesma, M. D., Martin, M. G., and Dotti, C. G. (2012). Lipid changes in the aged brain: effect on synaptic function and neuronal survival. Prog. Lipid Res. 51, 23–35. doi: 10.1016/j.plipres.2011.11.004
Lemkau, L. R., Comellas, G., Kloepper, K. D., Woods, W. S., George, J. M., and Rienstra, C. M. (2012). Mutant protein A30P alpha-synuclein adopts wild-type fibril structure, despite slower fibrillation kinetics. J. Biol. Chem. 287, 11526–11532. doi: 10.1074/jbc.M111.306902
Lewis, K. T., Maddipati, K. R., Naik, A. R., and Jena, B. P. (2017). Unique lipid chemistry of synaptic vesicle and synaptosome membrane revealed using mass spectrometry. ACS Chem. Neurosci. 8, 1163–1169. doi: 10.1021/acschemneuro.7b00030
Lewis, K. T., Maddipati, K. R., Taatjes, D. J., and Jena, B. P. (2014). Neuronal porosome lipidome. J. Cell Mol. Med. 18, 1927–1937. doi: 10.1111/jcmm.12383
Lindersson, E., Beedholm, R., Hojrup, P., Moos, T., Gai, W., Hendil, K. B., et al. (2004). Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 279, 12924–12934. doi: 10.1074/jbc.M306390200
Maraganore, D. M., de Andrade, M., Elbaz, A., Farrer, M. J., Ioannidis, J. P., Kruger, R., et al. (2006). Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296, 661–670. doi: 10.1001/jama.296.6.661
Middleton, E. R., and Rhoades, E. (2010). Effects of curvature and composition on alpha-synuclein binding to lipid vesicles. Biophys. J. 99, 2279–2288. doi: 10.1016/j.bpj.2010.07.056
Mokretar, K., Pease, D., Taanman, J. W., Soenmez, A., Ejaz, A., Lashley, T., et al. (2018). Somatic copy number gains of alpha-synuclein (SNCA) in Parkinson’s disease and multiple system atrophy brains. Brain 141, 2419–2431. doi: 10.1093/brain/awy157
Mor, D. E., Tsika, E., Mazzulli, J. R., Gould, N. S., Kim, H., Daniels, M. J., et al. (2017). Dopamine induces soluble alpha-synuclein oligomers and nigrostriatal degeneration. Nat. Neurosci. 20, 1560–1568. doi: 10.1038/nn.4641
Nakai, M., Fujita, M., Waragai, M., Sugama, S., Wei, J., Akatsu, H., et al. (2007). Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson’s disease, in erythropoietic lineage. Biochem. Biophys. Res. Commun. 358, 104–110. doi: 10.1016/j.bbrc.2007.04.108
Naudi, A., Cabre, R., Jove, M., Ayala, V., Gonzalo, H., Portero-Otin, M., et al. (2015). Lipidomics of human brain aging and Alzheimer’s disease pathology. Int. Rev. Neurobiol. 122, 133–189. doi: 10.1016/bs.irn.2015.05.008
Nemani, V. M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M. K., et al. (2010). Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 66–79. doi: 10.1016/j.neuron.2009.12.023
Nuber, S., Rajsombath, M., Minakaki, G., Winkler, J., Muller, C. P., Ericsson, M., et al. (2018). Abrogating native alpha-synuclein tetramers in mice causes a L-DOPA-responsive motor syndrome closely resembling Parkinson’s disease. Neuron 100, 75–90.e75. doi: 10.1016/j.neuron.2018.09.014
Perrin, R. J., Woods, W. S., Clayton, D. F., and George, J. M. (2001). Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem. 276, 41958–41962. doi: 10.1074/jbc.M105022200
Phan, J. A., Stokholm, K., Zareba-Paslawska, J., Jakobsen, S., Vang, K., Gjedde, A., et al. (2017). Early synaptic dysfunction induced by alpha-synuclein in a rat model of Parkinson’s disease. Sci. Rep. 7:6363. doi: 10.1038/s41598-017-06724-9
Pinho, R., Paiva, I., Jercic, K. G., Fonseca-Ornelas, L., Gerhardt, E., Fahlbusch, C., et al. (2018). Nuclear localization and phosphorylation modulate pathological effects of Alpha-Synuclein. Hum. Mol. Genet. 28, 31–50. doi: 10.1093/hmg/ddy326
Prots, I., Veber, V., Brey, S., Campioni, S., Buder, K., Riek, R., et al. (2013). alpha-Synuclein oligomers impair neuronal microtubule-kinesin interplay. J. Biol. Chem. 288, 21742–21754. doi: 10.1074/jbc.M113.451815
Rappley, I., Myers, D. S., Milne, S. B., Ivanova, P. T., Lavoie, M. J., Brown, H. A., et al. (2009). Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype. J. Neurochem. 111, 15–25. doi: 10.1111/j.1471-4159.2009.06290.x
Rovere, M., Powers, A. E., Jiang, H., Pitino, J. C., Fonseca-Ornelas, L., Patel, D. S., et al. (2019). E46K-like alpha-synuclein mutants increase lipid interactions and disrupt membrane selectivity. J. Biol. Chem. 294, 9799–9812. doi: 10.1074/jbc.RA118.006551
Rovere, M., Sanderson, J. B., Fonseca-Ornelas, L., Patel, D. S., and Bartels, T. (2018). Refolding of helical soluble alpha-synuclein through transient interaction with lipid interfaces. FEBS Lett. 592, 1464–1472. doi: 10.1002/1873-3468.13047
Ruf, V. C., Nubling, G. S., Willikens, S., Shi, S., Schmidt, F., Levin, J., et al. (2019). Different effects of alpha-synuclein mutants on lipid binding and aggregation detected by single molecule fluorescence spectroscopy and ThT fluorescence-based measurements. ACS Chem. Neurosci. 10, 1649–1659. doi: 10.1021/acschemneuro.8b00579
Sacket, S. J., Chung, H. Y., Okajima, F., and Im, D. S. (2009). Increase in sphingolipid catabolic enzyme activity during aging. Acta Pharmacol. Sin. 30, 1454–1461. doi: 10.1038/aps.2009.136
Schneider, J. S., Aras, R., Williams, C. K., Koprich, J. B., Brotchie, J. M., and Singh, V. (2019). GM1 ganglioside modifies alpha-synuclein toxicity and is neuroprotective in a rat alpha-synuclein model of Parkinson’s disease. Sci. Rep. 9:8362. doi: 10.1038/s41598-019-42847-x
Schneider, J. S., Cambi, F., Gollomp, S. M., Kuwabara, H., Brasic, J. R., Leiby, B., et al. (2015). GM1 ganglioside in Parkinson’s disease: pilot study of effects on dopamine transporter binding. J. Neurol. Sci. 356, 118–123. doi: 10.1016/j.jns.2015.06.028
Schneider, J. S., Gollomp, S. M., Sendek, S., Colcher, A., Cambi, F., and Du, W. (2013). A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson’s disease patients. J. Neurol. Sci. 324, 140–148. doi: 10.1016/j.jns.2012.10.024
Scott, D. A., Tabarean, I., Tang, Y., Cartier, A., Masliah, E., and Roy, S. (2010). A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J. Neurosci. 30, 8083–8095. doi: 10.1523/JNEUROSCI.1091-10.2010
Seyfried, T. N., Choi, H., Chevalier, A., Hogan, D., Akgoc, Z., and Schneider, J. S. (2018). Sex-related abnormalities in substantia nigra lipids in Parkinson’s disease. ASN Neurol. 10:1759091418781889. doi: 10.1177/1759091418781889
Shahmoradian, S. H., Lewis, A. J., Genoud, C., Hench, J., Moors, T. E., Navarro, P. P., et al. (2019). Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22, 1099–1109. doi: 10.1038/s41593-019-0423-2
Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A., and Selkoe, D. J. (2003). The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron 37, 583–595. doi: 10.1016/s0896-6273(03)00024-2
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., et al. (2003). alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302:841. doi: 10.1126/science.1090278
Snead, D., and Eliezer, D. (2014). Alpha-synuclein function and dysfunction on cellular membranes. Exp. Neurobiol. 23, 292–313. doi: 10.5607/en.2014.23.4.292
Soukup, S. F., Vanhauwaert, R., and Verstreken, P. (2018). Parkinson’s disease: convergence on synaptic homeostasis. EMBO J. 37:e98960. doi: 10.15252/embj.201898960
Spillantini, M. G., and Goedert, M. (2000). The alpha-synucleinopathies: parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N Y Acad. Sci. 920, 16–27. doi: 10.1111/j.1749-6632.2000.tb06900.x
Stefanis, L. (2012). alpha-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2:a009399. doi: 10.1101/cshperspect.a009399
Sulzer, D., and Edwards, R. H. (2019). The physiological role of alpha-synuclein and its relationship to Parkinson’s disease. J. Neurochem. 150, 475–486. doi: 10.1111/jnc.14810
Suzuki, M., Fujikake, N., Takeuchi, T., Kohyama-Koganeya, A., Nakajima, K., Hirabayashi, Y., et al. (2015). Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant alpha-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson’s disease. Hum. Mol. Genet. 24, 6675–6686. doi: 10.1093/hmg/ddv372
Takamori, S., Holt, M., Stenius, K., Lemke, E. A., Gronborg, M., Riedel, D., et al. (2006). Molecular anatomy of a trafficking organelle. Cell 127, 831–846. doi: 10.1016/j.cell.2006.10.030
Theillet, F. X., Binolfi, A., Bekei, B., Martorana, A., Rose, H. M., Stuiver, M., et al. (2016). Structural disorder of monomeric alpha-synuclein persists in mammalian cells. Nature 530, 45–50. doi: 10.1038/nature16531
Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., et al. (1993). Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90, 11282–11286. doi: 10.1073/pnas.90.23.11282
Uversky, V. N., Li, J., and Fink, A. L. (2001). Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276, 10737–10744. doi: 10.1074/jbc.M010907200
Vargas, K. J., Schrod, N., Davis, T., Fernandez-Busnadiego, R., Taguchi, Y. V., Laugks, U., et al. (2017). Synucleins have multiple effects on presynaptic architecture. Cell Rep. 18, 161–173. doi: 10.1016/j.celrep.2016.12.023
Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J., and Stefanis, L. (2011). Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol. 10, 1015–1025. doi: 10.1016/S1474-4422(11)70213-7
Vincent, B. M., Tardiff, D. F., Piotrowski, J. S., Aron, R., Lucas, M. C., Chung, C. Y., et al. (2018). Inhibiting Stearoyl-CoA desaturase ameliorates alpha-synuclein cytotoxicity. Cell Rep. 25, 2742–2754.e2731. doi: 10.1016/j.celrep.2018.11.028
Wang, L., Das, U., Scott, D. A., Tang, Y., McLean, P. J., and Roy, S. (2014). alpha-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr. Biol. 24, 2319–2326. doi: 10.1016/j.cub.2014.08.027
Wilhelm, B. G., Mandad, S., Truckenbrodt, S., Krohnert, K., Schafer, C., Rammner, B., et al. (2014). Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science 344, 1023–1028. doi: 10.1126/science.1252884
Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., et al. (2011). In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U.S.A. 108, 4194–4199. doi: 10.1073/pnas.1100976108
Keywords: alpha synuclein (α-syn), alpha synuclein accumulation, Parkisnon’s disease, lipid turnover, alpha synuclein oligomers
Citation: Kiechle M, Grozdanov V and Danzer KM (2020) The Role of Lipids in the Initiation of α-Synuclein Misfolding. Front. Cell Dev. Biol. 8:562241. doi: 10.3389/fcell.2020.562241
Received: 14 May 2020; Accepted: 26 August 2020;
Published: 15 September 2020.
Edited by:
Beate Winner, University of Erlangen Nuremberg, GermanyReviewed by:
Michele Vendruscolo, University of Cambridge, United KingdomIryna Prots, University Hospital Erlangen, Germany
Copyright © 2020 Kiechle, Grozdanov and Danzer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Karin M. Danzer, a2FyaW4uZGFuemVyQHVuaS11bG0uZGU=